FDA根据2项临床研究获得批准。 在第三阶段的NETTER-1研究(ClinicalTrials.gov标识符:NCT01578239)中,研究人员随机分配了229例生长抑素受体阳性GEP-NETs患者接受有或没有177Lu-dotatate的奥曲肽LAR。 截至数据截止时,177Lu-dotatate组患者的20个月无进展生存期为65.2%,而单独使用奥曲肽LAR的患者为10.8%。177Lu-dotatate...
177Lu-dotatate结合生长抑素受体,直接传递到肿瘤细胞中。 FDA根据2项临床研究获得批准。 在第三阶段的NETTER-1研究(ClinicalTrials.gov标识符:NCT01578239)中,研究人员随机分配了229例生长抑素受体阳性GEP-NETs患者接受有或没有177Lu-dotatate的奥曲肽LAR。 截至数据截止时,177Lu-dotatate组患者的20个月无进展生存期为...
177Lu-dotatate结合生长抑素受体,直接传递到肿瘤细胞中。 FDA根据2项临床研究获得批准。 在第三阶段的NETTER-1研究(ClinicalTrials.gov标识符:NCT01578239)中,研究人员随机分配了229例生长抑素受体阳性GEP-NETs患者接受有或没有177Lu-dotatate的奥曲肽LAR。 截至数据截止时,177Lu-dotatate组患者的20个月无进展生存期为...
177Lu-dotatate结合生长抑素受体,直接传递到肿瘤细胞中。 FDA根据2项临床研究获得批准。 在第三阶段的NETTER-1研究(ClinicalTrials.gov标识符:NCT01578239)中,研究人员随机分配了229例生长抑素受体阳性GEP-NETs患者接受有或没有177Lu-dotatate的奥曲肽LAR。 截至数据截止时,177Lu-dotatate组患者的20个月无进展生存期为...
These results provided an important validation that 177Lu-Dotatate not only improves progression-free survival (PFS) but also delays decline in quality of life and progression of symptoms. In the future, more randomized clinical trials should employ this emerging methodology to assess the impact of ...
Radionuclide therapy with ~(177)Lutetium DOTATATE is an increasingly proven treatment for the management of neuroendocrine cancers. Internationally several clinical trials were carried out to study the efficacy of this radionuclide therapy. DOTATATE is a compound containing tyorosine-octreotate, which can...
Based on its mechanism of action, LUTATHERA can cause fetal harm when administered to a pregnant woman [seeCLINICAL PHARMACOLOGY]. There are no available data on LUTATHERA use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female...
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
Assessment of response, clinical evaluation and toxicity of radioligand therapy (RLT) with 177-Lutetium-DKFZ-617-labeled prostate specific membrane antigen (177-Lu-DKFZ-617-PSMA) for metastatic castrate resistant prostate cancer (mCRPC): an initial experience in Jaslok. Conference: 29th Annual ...
Disease progression is defined as a 100% increase in PSA from baseline or clinical progression.This is the first prospective randomized clinical study assessing the therapeutic efficacy and toxicity of 177 Lu-PSMA-I&T for patients with oHSPC.Clinicaltrials.gov identifier: NCT04443062 . 展开 ...